F182112 single-agent

DRUG2 trials

Sponsors

Shandong New Time Pharmaceutical Co., LTD, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Autoimmune Hemolytic AnemiaRelapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia

Not yet recruitingNCT07816341

Institute of Hematology & Blood Diseases Hospital, ChinaAutoimmune Hemolytic Anemia

Start: 2026-10-10End: 2028-12-31Target: 12Updated: 2026-09-11

Phase 3

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

RecruitingNCT07579234

Shandong New Time Pharmaceutical Co., LTDRelapsed or Refractory Multiple Myeloma (RRMM)

Start: 2026-01-25End: 2029-01-25Target: 261Updated: 2026-05-12